Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Northwest Bioth Cmn (NWBO)

Northwest Bioth Cmn (NWBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 154,060
  • Shares Outstanding, K 562,262
  • Annual Sales, $ 410 K
  • Annual Income, $ -35,790 K
  • 60-Month Beta 1.81
  • Price/Sales 368.34
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2421 +10.29%
on 06/03/19
0.3400 -21.47%
on 05/31/19
-0.0513 (-16.12%)
since 05/24/19
3-Month
0.2421 +10.29%
on 06/03/19
0.3490 -23.50%
on 05/10/19
-0.0280 (-9.49%)
since 03/22/19
52-Week
0.1750 +52.57%
on 09/24/18
0.3500 -23.71%
on 03/14/19
-0.0100 (-3.61%)
since 06/22/18

Most Recent Stories

More News
Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO

NWBO : 0.2660 (-2.92%)
NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO

BETHESDA, Md. , May 30, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced...

NWBO : 0.2660 (-2.92%)
NW Bio Announces Settlement with Cognate BioServices Resolving Past Matters and Providing for Restart of DCVax®-Direct Production

Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement agreement...

NWBO : 0.2660 (-2.92%)
NW Bio Announces Settlement with Cognate BioServices Resolving Past Matters and Providing for Restart of DCVax®-Direct Production

BETHESDA, Md. , May 28, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today...

NWBO : 0.2660 (-2.92%)
Biotech Companies Intensify Research Into New Therapies to Combat Cancer

Cancer ranks among one of the top causes of death globally and data show that the number is still expected to increase. The National Cancer Institute stated in 2012 there were 14.1 million new cases of...

AST : 0.94 (unch)
NWBO : 0.2660 (-2.92%)
GNCA : 3.70 (+6.63%)
CYTR : 0.3300 (-0.30%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
NW Bio Hires David Innes As Vice President, Investor Relations

31 Years Managing Portfolios At Several Major Wall Street Firms, With Emphasis On Biotech

NWBO : 0.2660 (-2.92%)
NW Bio Hires David Innes As Vice President, Investor Relations

BETHESDA, Md. , Feb. 26, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

NWBO : 0.2660 (-2.92%)
NW Bio Releases Voting Results From Annual Shareholders' Meeting

NWBO : 0.2660 (-2.92%)
Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Focus on Complexity and Variability of Solid Tumors, and How DCVax(R)-L Addresses Them

NWBO : 0.2660 (-2.92%)
Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented...

NWBO : 0.2660 (-2.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade NWBO with:

Key Turning Points

2nd Resistance Point 0.2793
1st Resistance Point 0.2767
Last Price 0.2660
1st Support Level 0.2687
2nd Support Level 0.2633

See More

52-Week High 0.3500
Fibonacci 61.8% 0.2831
Last Price 0.2660
Fibonacci 50% 0.2625
Fibonacci 38.2% 0.2418
52-Week Low 0.1750

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar